![](/img/cover-not-exists.png)
32 A PHASE 1, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-ESCALATION STUDY OF IMO-2125, A TLR9 AGONIST, IN HEPATITIS C-NONRESPONDERS
A. Muir, R. Ghalib, E. Lawitz, K. Patel, M. Rodriguez-Torres, A. Sheikh, S. Sapp, R. Taylor, A. Bexon, T. Sullivan, A. Dovholuk, J. Mc HutchisonVolume:
52
Year:
2010
Language:
english
DOI:
10.1016/s0168-8278(10)60034-7
File:
PDF, 53 KB
english, 2010